PHP-303 is under clinical development by Peak Bio and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect PHP-303’s likelihood of approval (LoA) and phase transition for Alpha-1 Antitrypsin Deficiency (A1AD) took place on 16 Nov 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their PHP-303 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
PHP-303 (BAY-858501) is under development for the treatment of alpha-1 antitrypsin deficiency (AATD) and acute respiratory distress syndrome associated with COVID-19. It is administered through oral route as a film coated tablet. The drug candidate acts by targeting neutrophil elastase (NEI). It was also under development for the treatment of acute lung injury, non-alcoholic steatohepatitis (NASH) and non-cystic fibrosis bronchiectasis.
Peak Bio overview
Peak Bio is a biopharmaceutical company that engaged in developing and commercializing therapeutics for the treatment of oncology and inflammatory diseases. The company is headquartered in Palo Alto, California, the US.
Quick View PHP-303 LOA Data
|Highest Development Stage|